SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for Bysanti, a new treatment for bipolar I disorder and schizophrenia, which was granted New Chemical Entity (NCE) status with patent protection extending to 2044. The community is actively discussing this as a major re-rating catalyst, anticipating significant institutional buying, and speculating on the drug's blockbuster potential alongside future pipeline developments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

The recent acquisition of Astria Therapeutics, integrating the late-stage HAE drug navenibart, is driving BioCryst's conversation, especially with new data presentations for navenibart and Orladeyo expected at a medical conference and upcoming earnings. The community is actively discussing the potential of these pipeline advancements against persistent concerns about the stock's valuation and significant short interest.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending with strong community enthusiasm surrounding its anticipated BLA resubmission for deramiocel by the end of February, driving speculation for accelerated FDA approval and potential buyout interest, all while institutional ownership continues to increase.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community hotly debates the immense potential of its advanced GaN and SiC power platforms for next-gen AI data centers, particularly its role in NVIDIA's AI ecosystem. Despite the recognized breakthrough technology addressing critical efficiency needs, investors are expressing significant concern over the current absence of definitive, revenue-generating contracts, especially ahead of its upcoming earnings report.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending due to a dual financing announcement, including a non-dilutive royalty deal for its prostate cancer candidate and a concurrent public offering, which has sparked intense community debate over dilution and management's long-term commercialization strategy. Bulls view the capital raise as crucial validation and runway for its promising oncology pipeline, while bears express strong concerns about shareholder value and the impact on a potential "go it alone" approach.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending after receiving a prestigious Lightwave Award for its Teralight 1.6T product, intensifying community speculation for imminent major customer orders or partnerships in AI data center optical interconnects, even as some investors express frustration over management's continued silence and past capital raises.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following significant institutional investment and its impending inclusion in the MSCI USA Index, validating its strategic pivot to AI infrastructure. Community sentiment is deeply polarized, debating the company's vast secured power capacity and AI partnerships against concerns over valuation and broader sector volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending intensely following ANKTIVA's conditional marketing authorization across 33 European countries and accelerated approval in Saudi Arabia for lung cancer, sparking community excitement over immediate global revenue growth and an anticipated short squeeze, as many view Dr. Patrick Soon-Shiong's immunotherapy platform as an "unstoppable" force in cancer treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Computer racks in Data Center (Representative image courtesy of Arctic-Images via Getty Images)

AAOI Stock Pulls Back From 8-Year High As Traders Brace For Q4 Earnings

AI-based growth is pushing investor and retail optimism on Applied Optoelectronics higher as more data center growth continues to sprout.

Equity

AI-based growth is pushing investor and retail optimism on Applied Optoelectronics higher as more data center growth continues to sprout.


Applied Optoelectronics (NASDAQ:AAOI) Shares Up 7.4% - Here's What Happened

Applied Optoelectronics (NASDAQ:AAOI) Trading 7.4% Higher - Time to Buy...

WT Asset Management Ltd Acquires New Shares in Applied Optoelectronics, Inc. $AAOI

WT Asset Management Ltd bought a new position in shares of Applied Optoelectronics, Inc. (NASDAQ:AAOI - Free Report) during the 3rd quarter, according to its most recent filing with the Securities...

Applied Optoelectronics, Inc. (NASDAQ:AAOI) Given Average Recommendation of "Hold" by Brokerages

Applied Optoelectronics, Inc. (NASDAQ:AAOI - Get Free Report) has been assigned an average recommendation of "Hold" from the seven analysts that are currently covering the company, MarketBeat.com...

Garmin's Q4 Earnings Surpass Estimates, Revenues Rise Y/Y

GRMN tops Q4 EPS and revenue estimates as Fitness, Aviation and Marine drive double-digit sales growth, while 2026 outlook signals continued momentum.

Figma's Q4 Earnings Surpass Expectations, Revenues Rise Y/Y

FIG tops Q4 estimates as revenues jump 40% Y/Y to $303.7 million, boosts 2026 outlook to up to $1.374 billion amid strong customer expansion.

EPAM Systems Q4 Earnings and Revenues Surpass Estimates

EPAM's Q4 earnings and revenues beat estimates and register double-digit year-over-year growth, fueled by strong AI-driven growth across key sectors.

Rosenblatt Securities Reaffirms Buy Rating for Applied Optoelectronics (NASDAQ:AAOI)

Rosenblatt Securities reissued a "buy" rating and set a $50.00 price objective on shares of Applied Optoelectronics in a research report on Thursday...

Applied Optoelectronics (AAOI) to Release Quarterly Earnings on Thursday

Applied Optoelectronics (NASDAQ:AAOI) will be releasing its Q4 2025 earnings after the market closes on Thursday, February 26. (View Earnings Report at...

Sabre Shares Soar on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

SABR reports a narrower Q4 loss as revenues rise 3% on stronger air bookings.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Tech stocks

Energy

Cash / Bonds

Crypto

What&#39;s your biggest portfolio allocation right now?

Stocktwits

What's your biggest portfolio allocation right now?

Stocktwits Polls

Traders are keenly observing a significant short squeeze, pushing the stock price up sharply amidst high short interest and potential forced covering.

Discussion revolves around AAOI's critical role in next-gen AI with 800G transceivers and hyperscale orders, including specific mentions of Amazon contracts.

Speculation is circulating about a potential merger or acquisition, with mentions of "Merger Monday" and LITE potentially acquiring AAOI in a share-based deal.

Anticipation is building for the upcoming earnings call on February 26th, with speculation around guidance, potential contract announcements, and analyst questions.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.11	--	--	N/A
Q3 '25	-$0.09	-$0.09	2.16%	BEAT
Q2 '25	-$0.07	-$0.16	-123.99%	MISSED
Q1 '25	-$0.04	-$0.02	49.20%	BEAT
Q4 '24	-$0.02	-$0.02	-10.50%	MISSED

AAOI
Applied Optoelectronics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AAOI News

AAOIApplied Optoelectronics Inc